Treatment with pan-caspase inhibitors (VX-166 and IDN-7314) showed variable degrees of benefit in murine models of MASH.139,140 Emricasan, another pan-caspase inhibitor was evaluated in a RCT, including patients with decompensated MASH cirrhosis, which failed to show a benefit in terms of decompensation events and all-cause mortality.139,141,142 A selective CASP1 inhibitor reduced hepatic neutrophilic cell influx, TNF-α and hepatic fibrosis in a transgenicmurine MASH model.143. This evidence concerns the gene CASP1 and metabolic dysfunction-associated steatohepatitis.